Mesoblast limited Company Profile (OTCMKTS:MBLTY)

About Mesoblast limited (OTCMKTS:MBLTY)

Mesoblast limited logoMesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $12.26
  • 200 Day Moving Avg: $13.71
  • 52 Week Range: $10.27 - $19.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.07
  • P/E Growth: 0.00
  • Net Margins: -1,085.90%
  • Return on Equity: -7.47%
  • Return on Assets: -5.86%
  • Average Volume: 1,111 shs.
Frequently Asked Questions for Mesoblast limited (OTCMKTS:MBLTY)

What is Mesoblast limited's stock symbol?

Mesoblast limited trades on the OTCMKTS under the ticker symbol "MBLTY."

Where is Mesoblast limited's stock going? Where will Mesoblast limited's stock price be in 2017?

1 brokerages have issued twelve-month price objectives for Mesoblast limited's stock. Their forecasts range from $14.00 to $14.00. On average, they expect Mesoblast limited's stock price to reach $14.00 in the next year. View Analyst Ratings for Mesoblast limited.

Who are some of Mesoblast limited's key competitors?

Who are Mesoblast limited's key executives?

Mesoblast limited's management team includes the folowing people:

  • Silviu Itescu, Chief Executive Officer, Executive Director
  • William A. Burns, Vice Chairman of the Board
  • Paul Hodgkinson, Group Chief Financial Officer
  • Peter Howard, General Counsel, Corporate Executive
  • Charlie Harrison, Company Secretary
  • Brian Jamieson, Independent Non-Executive Chairman of the Board
  • Donal Paul O'Dwyer, Non-Executive Independent Director
  • Eric A. Rose M.D., Non-Executive Independent Director
  • Michael R. Spooner, Non-Executive Independent Director
  • Ben-Zion Weiner Ph.D., Non-Executive Independent Director

How do I buy Mesoblast limited stock?

Shares of Mesoblast limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast limited's stock price today?

One share of Mesoblast limited stock can currently be purchased for approximately $12.33.

MarketBeat Community Rating for Mesoblast limited (OTCMKTS MBLTY)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  56
MarketBeat's community ratings are surveys of what our community members think about Mesoblast limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mesoblast limited (OTCMKTS:MBLTY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00

Analysts' Ratings History for Mesoblast limited (OTCMKTS:MBLTY)
DateFirmActionRatingPrice TargetDetails
2/27/2017Maxim GroupSet Price TargetBuy$14.00View Rating Details
6/15/2016Credit Suisse GroupDowngradeHoldView Rating Details
6/15/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
(Data available from 8/16/2015 forward)


Earnings History for Mesoblast limited (OTCMKTS:MBLTY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Mesoblast limited (OTCMKTS:MBLTY)
Current Year EPS Consensus Estimate: $-1.43 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS


Dividend History for Mesoblast limited (OTCMKTS:MBLTY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mesoblast limited (OTCMKTS:MBLTY)
No insider trades for this company have been tracked by


Headline Trends for Mesoblast limited (OTCMKTS:MBLTY)
Latest Headlines for Mesoblast limited (OTCMKTS:MBLTY)
DateHeadline logoChina equities at 7-year highs; Tokyo struggles to cross 20,000 mark - April 7 at 11:04 AM logoMesoblast Investors Shrug Off Positive Phase 2a Trial Data - April 1 at 12:41 PM logoSearching for IPOs - November 13 at 2:08 PM logoKey United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions - October 27 at 9:07 PM logoMesoblast Chairman's Address to 2015 Annual General Meeting - October 22 at 2:00 AM logoCelgene and Mesoblast Extend Agreement - October 15 at 7:49 PM



Mesoblast limited (MBLTY) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by Staff